FRLCX | VGSIX | FRLCX / VGSIX | |
Total Expense Ratio | 1.93 | 0.27 | 715% |
Annual Report Gross Expense Ratio | 2.02 | 0.27 | 748% |
Fund Existence | 26 years | 29 years | - |
Gain YTD | 1.101 | 4.920 | 22% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 2500 | 0 | - |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 880M | 63.8B | 1% |
Annual Yield % from dividends | 2.56 | 3.75 | 68% |
Returns for 1 year | -1.38 | 8.10 | -17% |
Returns for 3 years | -16.25 | 9.41 | -173% |
Returns for 5 years | -8.03 | 41.03 | -20% |
Returns for 10 years | -26.90 | 63.27 | -43% |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
APCB | 29.40 | 0.02 | +0.07% |
ActivePassive Core Bond ETF | |||
XTR | 29.03 | N/A | N/A |
Global X S&P 500® Tail Risk ETF | |||
BIB | 52.55 | -0.07 | -0.14% |
ProShares Ultra Nasdaq Biotechnology | |||
FICS | 39.48 | -0.15 | -0.38% |
First Trust Intl Developed Cap Strth ETF | |||
IJR | 112.91 | -1.24 | -1.09% |
iShares Core S&P Small-Cap ETF |